Echinocandin antifungals: review and update

References

• Denning DW. Echinocandins and pneumocandins – a new antifungal class with a novel mode of action. J. Microb. Chemother.40, 611–614 (1997).
   PubMed Web of Science ®Google Scholar
• Nyfeler R, Keller SW. Metabolites of microorganisms, echinocandin B, a novel polypeptide antibiotic from Aspergillus nidulans var echinulatus – isolation and structural components. Helv. Chim. Acta57, 2459–2477 (1974).
   PubMed Web of Science ®Google Scholar
• Masurekar PS, Fountoulakis JM, Hallada TC et al. Pneumocandins from Zalerion arboricola, II: modification of product spectrum by mutation and medium manipulation. J. Antibiot. (Tokyo)45, 1867–1874 (1992).
   PubMed Web of Science ®Google Scholar
• Iwamoto T, Fujie A, Sakamoto K et al. WF11899A, B, and C, novel antifungal lipopeptides, I: taxonomy, fermentation, isolation, and physico-chemical properties.J. Antibiot. (Tokyo)47, 1084–1091 (1994).
   PubMed Web of Science ®Google Scholar
• Wong-Beringer A, Lambros M, Johnson D. Aerosolization potential of caspofungin (CAS). Proceedings of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. IL, USA (2003).
   Google Scholar
• Denning DW. Echinocandin antifungal drugs. Lancet362, 1142–1151 (2003).
   PubMed Web of Science ®Google Scholar
• Stone JA, Li S, Winchell S et al. Population pharmocokinetics of caspofungin in candidiasis patients. Program and Abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. IL, USA, Abstract A-1571 (2003).
   Google Scholar
• Walsh TJ, Adamson PC, Seibel NL et al. Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents. Antimicrob. Agents Chemother.49, 4536–4545 (2005).
   PubMed Web of Science ®Google Scholar
• Stone JA, Holland SD, Wickersham PJ et al. Single- and multiple-dose pharmacokinetics of caspofungin in healthy men. Antimicrob. Agents Chemother.46, 739–745 (2002).
   PubMed Web of Science ®Google Scholar
• Hajdu R, Thompson R, Sundelof JG et al. Preliminary animal pharmacokinetics of the parenteral antifungal agent MK-0991 (L-743,872). Antimicrob. Agents Chemother.41, 2339–2344 (1997).
   PubMed Web of Science ®Google Scholar
• Townsend R, Bekersky I, Buell DN et al. Pharmacokinetic (PK) evaluation of echinocandin FK463 in pediatric and adult patients. Proceedings of the 11th Focus on Fungal Infections Meeting. Washington, DC, USA, Abstract 24 (2001).
   Google Scholar
• Azuma J, Yamamoto I, Ogura M et al. Phase I study of FK463, a new antifungal agent, in healthy adult male volunteers. Proceedings of the 38th Interscience Conference on Antimicrob Agents and Chemother. CA, USA, Abstract F-146 (1998).
   Google Scholar
• Townsend R, Terakawa M, Bekersky I. PK/disposition of 14C/FK463, a novel echinocandin antifungal, in male volunteers. J. Clin. Pharmacol.40, 1048 (2000).
   Google Scholar
• Fromtling RA. Micafungin sodium (FK-463). Drugs Today38, 245–257 (2002).
   PubMed Web of Science ®Google Scholar
• Suzuki S, Terakawa M, Yokobayashi F et al. Pharmacokinetics of FK 463, a novel water-soluble echinocandin-like lipopeptide in animals. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. CA, USA, Abstract 144 (1998).
   Google Scholar
• Townsend R, Terakawa M, Bekersky I. Pharmacokinetics of FK463, a novel echinocandin antifungal, in bone marrow or peripheral stem cell transplant patients. J. Clin. Pharmacol.40, 1049 (2000).
   Google Scholar
• Seibel N, Schwartz C, Arrieta A et al. A Phase I study to determine the safety and pharmacokinetics (PK) of FK463 (echinocandin) in febrile neutropenic pediatric patients. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Ontario, Abstract 18 (2000).
   Google Scholar
• Mukai T, Ohkuma T, Nakahara K et al. Pharmacokinetics of FK463, a novel echinocandin analogue, in elderly and non-elderly subjects. Proceedings of the 41st Interscience Conference on Antimicrob Agents and Chemother. IL, USA (2001).
   Google Scholar
• Seibel NL, Schwartz C, Arrieta A et al. Safety, tolerability, and pharmacokinetics of micafungin (FK463) in febrile neutropenic pediatric patients. Antimicrob. Agents Chemother.49, 3317–3324 (2005).
   PubMed Web of Science ®Google Scholar
• Townsend R, Hebert M, Dessimoz M et al. Pharmacokinetics (PK) of micafungin, an echinocandin antifungal, in subjects with moderate hepatic dysfunction (MHD). Proceedings of the 31st Annual Meeting of the American College of Clinical Pharmacology. CA, USA (2002).
   Google Scholar
• Townsend R, Hebert M, Dessimoz M et al. Pharmacokinetics (PK) of micafungin, an echinocandin antifungal, in subjects with severe renal dysfuntion. Proceedings of the 31st Annual Meeting of the American College of Clinical Pharmacology. CA, USA (2002).
   Google Scholar
• Powles R, Sirohi B, Choppa R et al. Assessment of maximum tolerated dose (MTD) of FK463 in cancer patients undergoing haematopoietic stem cell transplantation. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. IL, USA, Abstract J-676 (2001).
   Google Scholar
• Odio CM, Araya R, Pinto LE et al. Caspofungin therapy of neonates with invasive candidiasis. Pediatr: Infect. Dis. J.23, 1093–1097 (2004).
   PubMed Web of Science ®Google Scholar
• Hesseling M, Weindling M, Neal T. First reported use of caspofungin in an extremely low-birth-weight neonate. J. Matern. Fetal Neonatal Med.14, 212 (2003).
   PubMedGoogle Scholar
• Cancidas® (caspofungin acetate) prescribing information. Merck & Co. (2005).
   Google Scholar
• Jarvis B, Figgitt DP, Scott LJ. Micafungin. Drugs64, 969–982 (2004).
   PubMed Web of Science ®Google Scholar
• Funguard® for infusion 50 mg. Funguard® for infusion 75mg (prescribing information). Fujisawa Pharmaceutical Co., Ltd., Japan (2003).
   Google Scholar
• Thirty-First Annual Meeting American College of Clinical Pharmacology September 21–23, 2002 San Francisco, California. J. Clin. Pharmacol.42, 1051–1071 (2002).
   Google Scholar
• Thye D, Kilfoil T, Kilfoil G, Henkel T. Anidulafungin: safety and pharmacokinetics in subjects receiving concomitant cyclosporine. Program and Abstracts of the 42th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. CA, USA, American Society of Microbiology, September 27–30, Abstract A-1836 (2002).
   Google Scholar
• Townsend R, Hebert M, Wisemandle W et al. Concomitant pharmacokinetics (PK) of micafungin, an echinocandin antifungal, and tacrolimus in healthy volunteers. Proceedings of the 31st Annual Meeting of the American College of Clinical Pharmacology. CA, USA (2002).
   Google Scholar
• Townsend R, Hebert M, Wisemandle W et al. Concomitant pharmacokinetics (PK) of micafungin, an echinocandin antifungal, and cyclosporine in healthy volunteers. Proceedings of the 31st Annual Meeting of the American College of Clinical Pharmacology. CA, USA (2002).
   Google Scholar
• Sanz-Rodriguez C, Lopez-Duarte M, Jurado M et al. Safety of the concomitant use of caspofungin and cyclosporin A in patients with invasive fungal infections. Bone Marrow Transpl.34, 1–8 (2004).
   PubMed Web of Science ®Google Scholar
• Marr KA, Hachem R, Papanicolaou G et al. Retrospective study of the hepatic safety profile of patients concomitantly treated with caspofungin and cyclosporin A. Transpl. Infect. Dis.6, 110–116 (2004).
   PubMedGoogle Scholar
• Trenschel R, Ditschkowski M, Elmaagacli AH et al. Caspofungin as second line therapy for fever of unknown origin or invasive fungal infection following allogeneic stem cell transplantation. Bone Marrow Transplant.35, 583–586 (2005).
   PubMed Web of Science ®Google Scholar
• Odds FC, Motyl M, Andrade R et al. Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species. J. Clin. Microbiol.42, 3475–3482 (2004).
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Messer SA, Boyken L et al. Further standardization of broth microdilution methodology for the in vitro susceptibility testing of caspofungin against Candida species by use of an international collection of more than 3,000 clinical isolates. J. Clin. Microbiol.42, 3117–3119 (2004).
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Messer SA, Boyken L et al. Geographic variation in the susceptibilities of invasive isolates of Candida glabrata to seven systemically active antifungal agents: a global assessment from the ARTEMIS Antifungal Survelillance Program conducted in 2001 and 2002. J. Clin. Microbiol.42, 3142–3146 (2004).
   PubMed Web of Science ®Google Scholar
• Marco F, Pfaller MA, Messer SA et al. Activity of MK-0991 (L-743,872), a new echinocandin, compared with those of LY303366 and four other antifungal agents tested against blood stream isolates of Candida spp. Diagn. Microbiol. Infect. Dis.31, 33–37 (1998).
   Web of Science ®Google Scholar
• Bartizal K, Gill CJ, Abruzzo GK et al. In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872). Antimicrob. Agents Chemother.41, 2326–2332 (1997).
   PubMed Web of Science ®Google Scholar
• Barchiesi F, Schimizzi AM, Fothergill AW et al. In vitro activity of the new echinocandin antifungal, MK-0991, against common and uncommon clinical isolates of Candida species. Eur. J. Clin. Microbiol. Infect. Dis.18, 302–304 (1999).
   PubMed Web of Science ®Google Scholar
• Ernst EJ, Klepser ME, Ernst ME et al. In vitro pharmacodynamic properties of MK-0991 determined by time-kill methods. Diagn. Microbiol. Infect. Dis.33, 75–80 (1999).
   PubMed Web of Science ®Google Scholar
• Espinel-Ingroff A. Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J. Clin. Microbiol.36, 2950–2956 (1998).
   PubMed Web of Science ®Google Scholar
• Vazquez JA, Lynch M, Biokov D et al. In vitro activity of a new pneumocandin antifungal, L-743,872, against azole-susceptible and -resistant Candida species. Antimicrob. Agents Chemother.41, 1612–1614 (1997).
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Jones RN, Doern GV et al. International surveillance of blood stream infections due to Candida species in European SENTRY program: species distribution and antifungal susceptibility including the investigational triazole and echinocandin agents. Diagn. Microbiol. Infect. Dis.35, 19–25 (1999).
   PubMed Web of Science ®Google Scholar
• Krishnarao TV, Galgiani JN. Comparison of the in vitro activities of the echinocandin LY303366, the pneumocandin MK-0991, and fluconazole against Candida species and Cryptococcus neoformans.Antimicrob. Agents Chemother.41, 1957–1960 (1997).
   PubMed Web of Science ®Google Scholar
• Colombo AL, Perfect J, DiNubile M et al. Global distribution and outcomes for Candida species causing invasive candidiasis: results from an international randomized double-blind study of caspofungin versus amphotericin B for the treatment of invasive candidiasis. Eur. J. Clin. Microbiol. Infect. Dis.22, 470–474 (2003).
   PubMed Web of Science ®Google Scholar
• Deresinski SC, Stevens DA. Caspofungin. Clin. Infect. Dis.36, 1445–1457 (2003).
   PubMed Web of Science ®Google Scholar
• Kartsonis N, Killar J, Mixson L et al. Caspofungin susceptibility testing of isolates from patients with esophageal candidiasis or invasive candidiasis: relationship of MIC to treatment outcome. Antimicrob. Agents Chemother.49, 3616–3623 (2005).
   PubMed Web of Science ®Google Scholar
• Kuhn DM, George T, Chandra J et al. Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins. Antimicrob. Agents Chemother.46, 1773–1780 (2002).
   PubMed Web of Science ®Google Scholar
• Bowman JC, Hicks PS, Kurtz MB et al. The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro. Antimicrob. Agents Chemother.46, 3001–3012 (2002).
   PubMed Web of Science ®Google Scholar
• Flattery AM, Hicks PS, Wilcox A et al. In vitro susceptibility of clinical trial isolates of Aspergillus spp. to the echinocandin antifungal Caspofungin (Cancidas™, MK-0991). 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Ontario, Abstract 936 (2000).
   Google Scholar
• Simmons EJ, Abruzzo G, Bowman J et al. Activity of caspofungin acetate against Aspergillus flavus, Asperillus terreus, and Aspergillus nidulans. Proceedings of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. IL, USA (2003).
   Google Scholar
• Chiller T, Farrokhshad K, Brummer E et al. The interaction of human monocytes, monocyte-derived macrophages, and polymorphonuclear neutrophils with caspofungin (MK-0991), an echinocandin, for antifungal activity against Aspergillus fumigatus. Diagn. Microbiol. Infect. Dis. 39, 99–103 (2001).
   PubMed Web of Science ®Google Scholar
• Chiller T, Farrokhshad K, Brummer E et al. Influence of human sera on the in vitro activity of the echinocandin caspofungin (MK-0991) against Aspergillus fumigatus.Antimicrob. Agents Chemother.44, 3302–3305 (2000).
   PubMed Web of Science ®Google Scholar
• Petraitiene R, Petraitis V, Groll AH et al. Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia. Antimicrob. Agents Chemother.46, 12–23 (2002).
   PubMed Web of Science ®Google Scholar
• Mora-Duarte J, Betts R, Rotstein C et al. for the caspofungin invasive candidiasis study group. Comparison of caspofungin and amphotericin B for invasive candidiasis. N. Engl. J. Med.347, 2020–2029 (2002).
   PubMed Web of Science ®Google Scholar
• Louie A, Deziel M, Liu W et al. Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity. Antimicrob. Agents Chemother.49, 5058–5068 (2005).
   PubMed Web of Science ®Google Scholar
• Graybill JR, Najvar LK, Montalbo EM et al. Treatment of histoplasmosis with MK-0991 (L-743,872). Antimicrob. Agents Chemother.42, 151–153 (1998).
   PubMed Web of Science ®Google Scholar
• Graybill JR, Bocanegra R, Luther M et al. Treatment of murine Candida krusei or Candida glabrata infection with L-743,872. Antimicrob. Agents Chemother.41, 1937–1939 (1997).
   PubMed Web of Science ®Google Scholar
• Kohler S, Wheat LJ. Connolly P et al. Comparison of the echinocandin casofungin with amphotericin B for the treatment of histoplasmosis following pulmonary challenge in a murine model. Antimicrob. Agents Chemother.44, 1850–1854 (2000).
   PubMed Web of Science ®Google Scholar
• Gonzalez GM, Tijerina R, Najyar LK et al. Efficacies of amphotericin B (AMB) lipid complex, AMB colloidal dispersion, liposimal AMB, and conventional AMB in treatment of murine coccidioidomycosis. Antimicrob. Agents Chemother.48, 2140–2143 (2004).
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Marco F, Messer SA et al. In vitro activity of two echinocandin derivatives, LY202255 and MK-0991 (L-473,792) against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi. Diagn. Microbiol. Infect. Dis.30, 251–255 (1998).
   PubMed Web of Science ®Google Scholar
• Spellberg B, Fu Y, Edwards JE Jr et al. Combination therapy with amphotericin B lipid complex and caspofungin acetate of disseminated zygomycosis in diabetic ketoacidotic mice. Antimicrob. Agents Chemother.49, 830–832 (2005).
   PubMed Web of Science ®Google Scholar
• Bocanegra R, Najvar LK, Hernandez S et al. Novel antifungal agents in murine scedosporiosis. Proceedings of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. IL, USA (2003).
   Google Scholar
• Spellberg B, Fu Y, Avanesian V et al. Treatment of experimental fusariosis using liposomal amphotericin B (LAmB), amphotericin B lipid complex (ABLC), amphotericin B deoxycholate (AmB), or caspofungin (CAS). Proceedings of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington DC, USA, Abstract B-49 (2005).
   Google Scholar
• Motyl MR, Nielsen Kahn J, Giacobbe RA. In vitro susceptibility of dermatophytes to CANCIDAS (caspofungin acetate). Proceedings of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. IL, USA (2003).
   Google Scholar
• Powles MA, Liberator P, Anderson J et al. Efficiacy of MK-0991 (L-743,872), a semisynthetic pneumocandin, in murine models of Pneumocystis carinii.Antimicrob. Agents Chemother.42, 1985–1989 (1998).
   PubMed Web of Science ®Google Scholar
• Moudgal V, Little T, Boikov D et al. Multiechinocandin- and multiazole-resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis. Antimicrob. Agents Chemother.49, 767–769 (2005).
   PubMed Web of Science ®Google Scholar
• Hernandez J, Lopez-Ribot JL, Najvar LK et al. Caspofungin resistance in Candida albicans: correlating clinical outcome with laboratory susceptibility testing of three isogenic isolates serially obtained from a patient with progressive Candida esophagitis. Antimicrob. Agents Chemother.48, 1382–1383 (2004).
   PubMed Web of Science ®Google Scholar
• Breit SM, Hariprasad SM, Mieler WF et al. Management of endogenous fungal endophthalmitis with voriconazole and caspofungin. Am. J. Ophthalmol.139, 135–140 (2005).
   PubMed Web of Science ®Google Scholar
• Edlind TD, Katiyar SK. Caspofungin-tolerant mutants of Candida albicans and Candida glabrata. Proceedings of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. IL, USA (2003).
   Google Scholar
• Park S, Kelly R, Kahn JN et al. Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida spp. isolates. Antimicrob. Agents Chemother.49, 3264–3273 (2005).
   PubMed Web of Science ®Google Scholar
• Osherov N, May GS, Albert ND et al. Overexpression of Sbe2p, a Golgi protein, results in resistance to caspofungin in Saccharomyces cerevisiae.Antimicrob. Agents Chemother.46, 2462–2469 (2002).
   PubMed Web of Science ®Google Scholar
• Schuetzer-Muehlbauer M, Willinger B, Krapf G et al. The Candida albicans Cdr2p ATP-binding cassette (ABC) transporter confers resistance to caspofungin. Mol. Microbiol.48, 225–235 (2003).
   PubMed Web of Science ®Google Scholar
• Stevens DA, Espiritu M, Parmar R. Paradoxical effect of caspofungin: reduced activity against Candida albicans at high drug concentrations. Antimicrob. Agents Chemother.48, 3407–3411 (2004).
   PubMed Web of Science ®Google Scholar
• Maertens J, Raad I, Sable CA et al. Multicenter, noncomparative study to evaluate safety and efficacy of caspofungin in adults with invasive aspergillosis refractory or intolerant to amphotericin B, amphotericin B lipid formulations, or azoles. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Ontario, Abstract 1103 (2000).
   Google Scholar
• Maertens J, Raad I, Petrikkos G et al. Efficacy and safety of caspofungin for treatent of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin. Infect. Dis.39, 1563–1571 (2004).
   PubMed Web of Science ®Google Scholar
• Kartsonis N, Saah A, Lipka J et al. Salvage therapy with caspofungin for invasive aspergillosis: results from the caspofungin compassionate use study. J. Infect.50, 196–205 (2005).
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Teppler H, Donowitz GR et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N. Engl. J. Med.351, 1391–1402 (2004).
   PubMed Web of Science ®Google Scholar
• Villanueva A, Arathoon EG, Gotuzzo E et al. A randomized, double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis. Clin. Infect. Dis.33, 1529–1535 (2001).
   PubMed Web of Science ®Google Scholar
• Caspofungin (Cancidas) for aspergillosis. The Medical Letter43, 58–59 (2001).
   Google Scholar
• Villanueva A, Gotuzzo E, Arathoon EG et al. A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Am. J. Med.113, 294–299 (2002).
   PubMed Web of Science ®Google Scholar
• Mrowczynski W, Wojtalik M. Caspofungin for Candida endocarditis. Pediatr. Infect. Dis. J.23, 376 (2004).
   PubMed Web of Science ®Google Scholar
• Karsonis NA, Saah A, Lipka CJ et al. Second-line therapy with caspofungin for mucosal or invasive candidiasis: results from the caspofungin compassionate-use study. J. Antimicrob. Chemother.53, 878–881 (2004).
   PubMed Web of Science ®Google Scholar
• Mattiuzzi GN, Alvarado G, Giles FJ et al. Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies. Antimicrob. Agents Chemother.50, 143–147 (2006).
   PubMed Web of Science ®Google Scholar
• Ernst EJ, Roling EE, Petzold CR et al. In vitro activity of micafungin (FK-463) against Candida spp.: microdilution, time-kill, and postantifungal-effect studies. Antimicrob. Agents Chemother.46, 3846–3853 (2002).
   PubMed Web of Science ®Google Scholar
• Laverdiere M, Hoban D, Restieri C et al. In vitro activity of three new triazoles and one echinocandin against Candida bloodstream isolates from cancer patients. J. Antimicrob. Chemother.50, 119–123 (2002).
   PubMed Web of Science ®Google Scholar
• Iwamoto T, Sakamoto N, Yamashita M et al. FR901379, a novel antifungal antibiotic. 33rd Interscience Conference of Antimicrobial Agents and Chemotherapy. LA, USA, Abstract 371 (1993).
   Google Scholar
• Ostrosky-Zeichner L, Paetznick VL, Mohr J et al. In vitro antifungal activity of FK-463 against Candida spp. 40th Interscience Conference of Antimicrobial Agents and Chemotherapy. Toronto, Ontario, Abstract 197 (2000).
   Google Scholar
• Muller FC, Kurzai O, Bautsch W et al. In vitro comparative activity of FK463, fluconazole (FCZ), flucytosine (5-FC), amphotericin B (AMB), and voriconazole (VCZ), against clinical Candida albicans and Candida dubliniensis isolates and a comparison of RPMI 2%, AM3 2%, and HR medium. 40th Interscience Conference of Antimicrobial Agents and Chemotherapy. Toronto, Ontario, Abstract 195 (2000).
   Google Scholar
• Muller FM, Kurzai O, Hacker J et al. Effect of the growth medium on the in vitro antifungal activity of micafungin (FK-463) against clinical isolates of Candida dubliniensis.J. Antimicrob. Chemother.48, 713–715 (2001).
   PubMed Web of Science ®Google Scholar
• Ernst EJ, Petzold CR, Roling EE et al. Effects of protein binding and in vitro activity of FK463. Pharmacotherapy21, 383 (2001).
   Google Scholar
• Mikamo H, Sata Y, Tamaya T. In vitro antifungal activity of FK463, a new water-soluble echinocandin-like lipopeptide. J. Antimicrob. Chemother.46, 485–487 (2000).
   PubMed Web of Science ®Google Scholar
• Takakura S, Fujihara N, Saito T et al. National surveillance of species distribution in blood isolates of Candida species in Japan and their susceptibility to six antifungal agents including voriconazole and micafungin. J. Antimicrob. Chemother.53, 283–289 (2004).
   PubMed Web of Science ®Google Scholar
• Wiederhold NP, Lewis RE. The echinocandin antifungals: an overview of the pharmacology, spectrum and clinical efficacy. Expert Opin. Investig. Drugs12, 1313–1333 (2003).
   PubMed Web of Science ®Google Scholar
• Ostrosky-Zeichner L, Rex JH, Pappas PG et al. Antifungal susceptibility survey of 2000 bloodstream Candida isolates in the United States. Antimicrob. Agents Chemother.47, 3149–3154 (2003).
   PubMed Web of Science ®Google Scholar
• Manavathu EK, Ganesan LT, Cutright PH et al. In vitro antifungal activity of voriconazole in two-drug combination with micafungin, caspofungin and amphotericin B. Proceedings of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. IL, USA, Abstract J-125 (2001).
   Google Scholar
• Steinbach WJ, Stevens DA, Denning DW. Combination and sequential antifungal therapy for invasive aspergillosis: review of published in vitro and in vivo interactions and 6281 clinical cases from 1966 to 2001. Clin. Infect. Dis.37, S188–S224 (2003).
   PubMed Web of Science ®Google Scholar
• Tawara S, Ikeda F, Maki K et al. In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi. Antimicrob. Agents Chemother.44, 57–62 (2000).
   PubMed Web of Science ®Google Scholar
• Tomishima M, Ohki H, Yamada A et al. FK463, a novel water-soluble echinocandin lipopeptide: synthesis and antifungal activity. J. Antibiot. (Tokyo)52, 674–676 (1999).
   PubMed Web of Science ®Google Scholar
• Uchida C, Nishiyama Y, Yokota N et al. In vitro antifungal activity of a novel lipopeptide antifungal agent, FK463, against various fungal pathogens. J. Antibiot. (Tokyo)53, 1175–1181 (2000).
   PubMed Web of Science ®Google Scholar
• Choi JH, Brummer E, Stevens DA. Combined action of micafungin, a new echinocandin, and human phagocytes for antifungal activity against Aspergillus fumigatus. Microbes Infect.6, 383–389 (2004).
   PubMed Web of Science ®Google Scholar
• Zeng J, Kamei K, Zheng J et al. Susceptibility of Pseudoallescheria boydii and Scedosporium apiospermum to new antifungal agents. Jap. J. Med. Mycol.45, 101–104 (2004).
   Google Scholar
• Ikeda F, Wakai Y, Matsumoto S et al. Efficacy of FK463, a new lipopeptide antifungal agents, in mouse models of disseminated candidiasis and aspergillosis. Antimicrob. Agents Chemother.44, 614–618 (2000).
   PubMed Web of Science ®Google Scholar
• Maesaki S, Hossan MA, Miyazaki Y et al. Efficacy of FK463, a (1,3)-β-d-glucan synthase inhibitor, in disseminated azole-resistant Candida albicans infection in mice. Antimicrob. Agents Chemother.44, 1728–1730 (2000).
   PubMed Web of Science ®Google Scholar
• Kohno S, Niki Y, Takematsu Y et al. The latest diagnosis and treatment on deep-seated mycoses. Expectations for micafungin, the first candin in Japan. Jpn J. Antibiot.56, 1–14 (2003).
   PubMedGoogle Scholar
• Matsumoto S, Wakai Y, Nakai T et al. Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of pulmonary aspergillosis. Antimicrob. Agents Chemother.44, 619–621 (2000).
   PubMed Web of Science ®Google Scholar
• Groll AH, Mickiene D, Petraitis V et al. Compartmental pharmocokinetics and tissue distribution of the antifungal echinocandin lipopeptide micafungin (FK463) in rabbits. Antimicrob. Agents Chemother.45, 3322–3327 (2001).
   PubMed Web of Science ®Google Scholar
• Petraitis V, Petraitien R, Groll AH et al. Comparative antifungal activities and plasma pharmocokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob. Agents Chemother.46, 1857–1869 (2002).
   PubMed Web of Science ®Google Scholar
• Ito M, Nozu R, Kuramochi T et al. Prophylactic effect of FK463, a novel antifungal lipopeptide, against Pneumocystis carinii infection in mice. Antimicrob. Agents Chemother.44, 2259–2262 (2000).
   PubMed Web of Science ®Google Scholar
• Borg-von Zepelin M, Zaschke K, Gross U et al. Effect of micafungin (FK463) on Candida albicans adherence to epithelial cells. Chemotherapy48, 148–153 (2002).
   PubMed Web of Science ®Google Scholar
• Kohno S, Masoaka T, Yamaguchi H et al. A multicenter, open-label clinical study of micafungin (FK463) in the treatment of deep-seated mycosis in Japan. Scand. J. Infect. Dis.36, 372–379 (2004).
   PubMed Web of Science ®Google Scholar
• Pettengell K, Mynhardt J, Kluyta R et al. Successful treatment of oesophageal candidiasis by micafungin: a novel systemic anifungal agent. Aliment. Pharmacol. Ther.20, 475–481 (2004).
   PubMed Web of Science ®Google Scholar
• De Wet N, Llanos-Cuentas A, Suleiman J et al. A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients. Clin. Infect. Dis.39, 842–849 (2004).
   PubMed Web of Science ®Google Scholar
• Suleiman J, Della Negra M, Llanos-Cuentas A et al. Open label study of micafungin in the treatment of esophageal candidiasis (EC). Proceedings of the 42nd Conference on Antimicrobial Agents and Chemotherapy, CA, USA, Abstract M-892 (2002).
   Google Scholar
• Ostrosky-Zeichner L, Kontoyiannis D, Raffali J et al. International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia. Eur. J. Clin. Microbiol. Infect. Dis.24, 654–661 (2005).
   PubMed Web of Science ®Google Scholar
• Ullmann AJ, Van Burik JA, McSweeney P et al. An open phase II study of the efficacy of micafungin alone and in combination for the treatment of invasive aspergillosis (IA) in adults and children. Clin. Microbiol. Infect.9, 6 (2003).
   Google Scholar
• Ratanatharathorn V, Flynn P, Van Buril J-A et al. Micafungin in combination with systemic antifungal agents in the treatment of refractory aspergillosis (RA) in bone marrow transpl.ant (BMT) patients. Proceedings of the 44th Annual Meeting of the American Society of Hematology. PA, USA, Abstract 2472 (2002).
   Google Scholar
• van Burik JH, Ratanatharathorn V, Stepan DE et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin. Infect. Dis.39, 1407–1416 (2004).
   PubMed Web of Science ®Google Scholar
• Powles R, Sirohi B, Chopra R et al. Use of FK463, a novel echinocandin analog in patients undergoing stem cell transplantation (SCT) for hematologic malignancies, a matched pair comparison of biochemical toxicity with historical controls. Bone Marrow Transpl.29, S247 (2002).
   Google Scholar
• Powles R, Sirohi B, Chopra R et al. Assessment of maximum tolerated dose and pharmacokinetics of FK463 in neutropenic patients after haematopoietic stem cell transplantation. Blood98, 361 (2001).
   Google Scholar
• Kontoyiannis DP, Buell D, Frisbee-Hume S et al. Initial experience with FK463 for the treatment of candidemia in cancer patients. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. IL, USA, Abstract J-1629 (2001).
   Google Scholar
• Yokote T, Akika T, Oka S et al. Successful treatment with micafungin of invasive pulmonary aspergillosis in acute myeloid leukemia, with renal failure due to amphotericin B therapy. Ann. Hematol.83, 64–66 (2004).
   PubMed Web of Science ®Google Scholar
• Ota S, Tanaka J, Kahata K et al. Successful micafungin (fk463) treatment of invasive pulmonary asperigillosis in a patient with acute lymphoblastic leukemia in a Phase II study. Int. J. Hematol.79, 390–393 (2004).
   PubMed Web of Science ®Google Scholar
• Singer MS, Seibel NL, Vezina G et al. Successful treatment of invasive aspergillosis in two patients with acute myelogenous leukemia. J. Pediatr. Hematol. Oncol.25, 252–256 (2003).
   PubMed Web of Science ®Google Scholar
• Raasch RH. Anidualfungin: review of a new echinocandin antifungal agent. Expert Rev. Anti Infect. Ther.2, 499–508 (2004).
   PubMedGoogle Scholar
• Hector FR. Compounds active against cell walls of medically important fungi. Clin. Microbiol. Rev.6, 1–21 (1993).
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Messer SA, Coffman S. In vitro susceptibilities of clinical yeasts isolates to a new echinocandin derivative, LY303366, and other antifungal agents. Antimicrob. Agents Chemother.41, 763–766 (1997).
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Boyken L, Hollis RJ et al. In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole. J. Clin. Microbiol.43, 5425–5427 (2005).
   PubMed Web of Science ®Google Scholar
• Arevalo MP, Carrillo-Munoz AJ, Salgado J et al. Antifungal activity of the echinocandin anidulafungin (VER002, LY-303366) against yeast pathogens: a comparative study with M27-A microdilution method. J. Antimicrob. Chemother.51, 163–166 (2003).
   PubMed Web of Science ®Google Scholar
• Marco F, Danes C, Almela M et al. Trend in frequency and in in vitro susceptibilities to antifungal agents, including voriconazole and anidulafungin, of Candida bloodstream isolates. Results from a six year study (1996–2001). Diag. Microbiol. Infect. Dis.46, 259–264 (2003).
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Hollis R, Goldstein BP et al. In vitro activity of anidulafungin (ANID) and other agents against 526 esophageal candidiasis (EC) isolates. Proceedings of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, IL, USA (2003).
   Google Scholar
• Groll AH, Mickiene D, Petraitiene R et al. Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling. Antimicrob. Agents Chemother.45, 2845–2855 (2001).
   PubMed Web of Science ®Google Scholar
• Serrano MC, Valverde-Conde A, Chavez MM et al. In vitro activity of voriconazole, itraconazole, caspofungin, anidulafungin (VER002, LY303366) and amphotericin B against Aspergillus species. Diagn. Microbiol. Infect. Dis.45, 131–135 (2003).
   PubMed Web of Science ®Google Scholar
• Odabasi Z, Paetznick VL, Rodriguez JR et al. In vitro activity of anidulafungin against selected clinically important mold isolates. Antimicrob. Agents Chemother.48, 1912–1915 (2004).
   PubMed Web of Science ®Google Scholar
• Krause DS, Reinhardt J, Vazquez JA et al. Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia. Antimicrob. Agents Chemother.2021–2024 (2004).
   PubMed Web of Science ®Google Scholar
• Krause DS, Simjee AE, van Rensburg C et al. A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis. Clin. Infect. Dis.39, 770–775 (2004).
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Diekema DJ, Boyken L et al. Effectiveness of anidulafungin in eradicating Candida species in invasive candidiasis. Antimicrob. Agents Chemother.49, 4795–4797 (2005).
   PubMed Web of Science ®Google Scholar
• Reboli A, Rotstein C, Pappas P et al. Anidualfungin versus fluconazole for treatment of candidemia and invasive candidiasis (C/IC). Proceedings of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington DC, USA, Abstract M-718 (2005).
   Google Scholar
• Johnson MD, MacDougall C, Ostrosky-Zeichner L et al. Combination antifungal therapy. Antimicrob. Agents Chemother.48, 693–715 (2004).
   PubMed Web of Science ®Google Scholar
• Roling EE, Klepser ME, Wasson A et al. Antufungal activities of fluconazole, caspofungin (MK0991), and anidulafungin (LY 303366) alone and in combination against Candida species and Cryptococcus neoformans via time-kill methods. Diagn. Microbiol. Infect. Dis.43, 13–17 (2002).
   PubMed Web of Science ®Google Scholar
• Petraitis V, Petraitiene R, Sarafandi AA et al. Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin. J. Infect. Dis.187, 1834–1843 (2003).
   PubMed Web of Science ®Google Scholar
• Gil Lamaignere C, Muller FM. Differential effects of the combination of caspofungin and terbinafine against Candida albicans, Candida dubliniensis and Candida kefyr.Int. J. Antimicrob. Agents23, 520–523 (2004).
   PubMed Web of Science ®Google Scholar
• Perea S, Gonzalez G, Fothergill AW et al. In vitro interaction of caspofungin acetate with voriconazole against clinical isolates of Aspergillus species. Antimicrob. Agents Chemother.46, 3039–3041 (2002).
   PubMed Web of Science ®Google Scholar
• Kohno S, Maesaki S, Iwakawa J et al. Synergistic effects of combination of FK463 with amphotericin B: enhanced efficacy in murine model of invasive pulmonary aspergillosis. Program and Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Ontario, Abstract 1686 (2000).
   Google Scholar
• Nakajima M, Tamada S, Toshida K et al. Pathological findings in a murine pulmonary aspergillosis model: treatment with FK463, amphotericin B and a combination of FK463 and amphotericin B. Program and Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Ontario, Abstract 1685 (2000).
   Google Scholar
• Arikan S, Lozano-Chiu M, Paetznick V et al. In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp. Antimicrob. Agents Chemother.46, 245–247 (2002).
   PubMed Web of Science ®Google Scholar
• Cuenca-Estrella M, Gomez-Lopez A, Garcia-Effron G et al. Combined activity in vitro of caspofungin, amphotericin B, and azole agents against itraconazole-resistant clinical isolates of Aspergillus fumigatus. Antimicrob. Agents Chemother.49, 1232–1235 (2005).
   PubMed Web of Science ®Google Scholar
• Sabatelli F. In vitro and in vivo interaction of posaconazole (POS) and caspofungin (CSP) against Aspergillus. Proceedings of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. IL, USA (2003).
   Google Scholar
• Chiou CC, Mavrogiorgos N, Tillem E et al. Synergy, pharmacodynamics, and time-sequenced ultrastructural changes of the interaction between nikkomycin Z and the echinocandin FK463 against Aspergillus fumigatus. Antimicrob. Agents Chemother.45, 3310–3321 (2001).
   PubMed Web of Science ®Google Scholar
• Stevens DA. Drug interaction in vitro between a polyene (AmBisone; Ambi) and an echinocandin (FK463; FK) vs. Aspergillus species. Proceedings of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. CA, USA (1999).
   Google Scholar
• Ostrosky-Zeichner L, Matar M, Paetznick VL et al. In-vitro synergy testing of anidulafungin (AFG) and micafungin (MFG) in combination with amphotericin B (AMB) against Aspergillus spp. and Fusarium spp. Proceedings of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. CA, USA, Abstract M-1816 (2002).
   Google Scholar
• O’Shaughnessy EM, Peter J, Walsh TJ. In vitro additive and synergistic effect of two echinocandins, caspofungin and micafungin with voriconazole against Aspergillus fumigatus. Proceedings of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. CA, USA, Abstract M-856 (2002).
   Google Scholar
• Philip A, Odabasi Z, Rodriguez JR et al. In vitro synergy testing of anidulafungin (ANID) with itraconazole (ITR) and voriconazole (VOR) against Aspergillus spp. and Fusarium spp. Proceedings of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. IL, USA (2003).
   Google Scholar
• Warn PA, Sharp A, Morrissey G et al. In vivo activity of micafungin in a persistently neutropenic murine model of disseminated infection caused by Candida tropicalis. J. Antimicrob. Chemother.50, 1071–1074 (2002).
   PubMed Web of Science ®Google Scholar
• Wheat LJ. Combination therapy for aspergillosis: is it needed, and which combination? J. Infect. Dis.187, 1831–1833 (2003).
   PubMed Web of Science ®Google Scholar
• Luque JC, Clemons KV, Stevens DA. Efficacy of micafungin alone or in combination against systemic murine aspergillosis. Antimicrob. Agents Chemother.47, 1452–1455 (2003).
   PubMed Web of Science ®Google Scholar
• Warn PA, Morrissey G, Morrissey J et al. Activity of micafungin (FK463) against an itraconazole-resistant strain of Aspergillus fumigatus and a strain of Aspergillus terreus demonstrating in vivo resistance to amphotericin B. J. Antimicrob. Chemother.51, 913–919 (2003).
   PubMed Web of Science ®Google Scholar
• Marr K. Combination antifungal therapy: where are we now, and where are we going? Oncology18(Suppl. 7), 24–29 (2004).
   PubMedGoogle Scholar
• Aliff TB, Maslak PG, Jurcic JG et al. Refractory Aspergillus pneumonia in patients with acute leukemia – successful therapy with combination caspofungin and liposomal amphotericin. Cancer97, 1025–1032 (2003).
   PubMed Web of Science ®Google Scholar
• Thiebaut A Sr, Antal D, Breysse MC et al. Refractory invasive fungal infections in patients with hematologic malignancies: combination of new antifungal agents (voriconazole or caspofungin) with amphotericin B. Program and Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. CA, USA (2002).
   Google Scholar
• Castagnola E, Machetti M, Cappelli B et al. Caspofungin associated with liposomal amphotericin B or voriconazole for treatment of refractory fungal pneumonia in children with acute leukaemia or undergoing allogeneic bone marrow transplantation.Clin. Microbiol. Infect.10(3), 255–257 (2004).
   PubMed Web of Science ®Google Scholar
• Hubel K, Chemnitz J, Brochhagen HG. Successful treatment of chronic disseminated candidiasis with caspofungin and itraconazole in a patient with progressive acute leukemia and prolonged neutropenia. Int. J. Hematol.79, 289–292 (2004).
   PubMed Web of Science ®Google Scholar
• Wertz KK, Pretzlaff RK. Caspofungin in a pediatric patient with persistent candidemia. Pediatr. Crit. Care Med.5, 181–183 (2004).
   PubMedGoogle Scholar
• Kontoyiannis DP, Hachem R, Lewis RE et al. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer98, 292–299 (2003).
   PubMed Web of Science ®Google Scholar
• Gentina T, De Botton S, Alfandari S et al. Combination antifungals for treatment of pulmonary invasive aspergillosis (IA) refractory to amphotericin B (AmB) in leukaemia patients. Program and Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. CA, USA (2002).
   Google Scholar
• Steinbach WJ, Schell WA, Miller JL et al. Fatal Scopulariopsis brevicaulis infection in a paediatric stem-cell transplant patient treated with voriconazole and caspofungin and a review of scopulariopsis infections in immunocompromised patients. J. Infect.48, 112–116 (2004).
   PubMed Web of Science ®Google Scholar
• Marr KA, Boeckh M, Carter RA et al. Combination antifungal therapy for invasive aspergillosis. Clin. Infect. Dis.39, 797–802 (2004).
   PubMed Web of Science ®Google Scholar
• Singh N, Limaye A, Safdar N et al. Combination of voriconazole (VRC) and caspofungin (CAS) as primary therapy for invasive aspergillosis (IA) in solid organ transplant (SOT) recipients. Proceedings of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington DC, USA, Abstract M-717 (2005).
   Google Scholar
• Cesaro S, Toffolutti T, Messina C et al. Safety and efficacy of caspofungin and liposomal amphotericin B, followed by voriconazole in young patients affected by refractory invasive mycosis. Eur. J. Haematol.73, 50–55 (2004).
   PubMed Web of Science ®Google Scholar
• Maertens J, Glasmacher A, Herbrecht R et al. Multicenter, noncomparative study of caspofungin (CAS) combined with other antifungals in adults with invasive Aspergillosis (IA) refractory (R) or intolerant (I) to prior therapy (Rx): final data. Proceedings of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington DC, USA, Abstract M-954 (2005).
   Google Scholar
• Viscoli C. Combination therapy for invasive aspergillosis. Clin. Infect. Dis.39, 803–805 (2004).
   PubMed Web of Science ®Google Scholar
• Cesaro S, Visintin G. Combination antifungal therapy for invasive aspergillosis. Clin. Infect. Dis.40, 1073–1075 (2005).
   PubMed Web of Science ®Google Scholar
• Marr KA, Boeckh M, Kim HW. Reply to Cesaro and Visintin. Clin. Infect. Dis.40(7), 1075–1076 (2005).
   Web of Science ®Google Scholar
• Ohyama T, Kurihara Y, Ono Y et al. Arborcandins A, B, C, D, E and F, novel 1,3-beta-glucan synthase inhibitors: production and biological activity.J. Antibiot.53, 1108–1116 (2000).
   PubMed Web of Science ®Google Scholar
• Onishi J, Meinz M, Thompson J et al. Discovery of novel antifungal (1,3)-d-glucan synthase inhibitors. Antimicrob. Agents Chemother.44, 368–377 (2000).
   PubMed Web of Science ®Google Scholar
• Pelaez F, Cabello A, Platas G et al. The discovery of enfumafungin, a novel antifungal compound produced by endophytic Hormonema species – biological activity and taxonomy of the producing organisms. Syst. Appl. Microbiol.23, 333–343 (2000).
   PubMed Web of Science ®Google Scholar